Madrid, Spain – An off-label treatment with efgartigimod successfully helped manage severe, treatment-resistant Lambert-Eaton myasthenic syndrome (LEMS) in a 20-year-old woman in Spain whose disease had left her unable to walk independently or carry out basic daily activities. Following treatment, she regained significant mobility and independence, eventually becoming able to walk 200 meters (approximately 656 feet) without assistance, according to a case report.
The woman had non-tumor-associated LEMS, meaning her condition was not linked to an underlying cancer. Her healthcare team turned to efgartigimod after several conventional treatment approaches failed to provide lasting benefits.
The medication, marketed by Argenx as Vyvgart Hytrulo in its subcutaneous (under-the-skin) formulation, is approved for treating myasthenia gravis (MG), another autoimmune neuromuscular disorder. Although not approved for LEMS, efgartigimod was used off-label in this case because of the similarities between the two diseases.
The findings were described in a study titled “Case Report: Efgartigimod in refractory non-tumor Lambert-Eaton myasthenic syndrome,” published in Frontiers in Immunology.
“To the best of our knowledge, we present the first published primary non-tumor-LEMS case treated successfully with efgartigimod after years of disease evolution and insufficient control with classical immunosuppressive drugs,” the researchers wrote.
They said the case highlights the potential of efgartigimod for people with treatment-resistant LEMS, emphasizing that long disease duration should not prevent patients from being considered for targeted therapies.
Two years of worsening symptoms before LEMS diagnosis
The woman initially sought medical attention after experiencing several months of progressive leg weakness that made running and climbing stairs increasingly difficult. Over time, the weakness spread to her shoulders and arms and became more pronounced with sustained physical activity.
A neurological examination revealed weakness in her leg and neck muscles, reduced reflexes, and mild drooping of one eyelid.
Initial tests examining electrical activity in her muscles suggested a problem with communication between nerves and muscles. However, blood tests for antibodies commonly associated with MG were negative.
She was initially treated with pyridostigmine and prednisone, an anti-inflammatory and immunosuppressive medication. However, these treatments provided only mild and inconsistent improvements, while her condition continued to deteriorate.
Eventually, she became unable to perform basic daily activities or walk 100 meters (approximately 328 feet) without assistance.
Further investigations revealed abnormal electrical responses characteristic of LEMS and antibodies targeting voltage-gated calcium channel proteins, which are involved in the disease. These findings confirmed her LEMS diagnosis approximately two years after her symptoms first appeared.
Repeated imaging examinations found no evidence of an underlying cancer, establishing that her condition was not tumor-associated.
Several conventional treatments failed to control the disease
Despite receiving multiple treatments over approximately three years, including Firdapse (amifampridine), immunosuppressive medications, and plasma exchange (a procedure that removes harmful antibodies from the blood), the woman’s condition continued to worsen.
“Multiple immunosuppressive therapies were administered, without sustained clinical benefit and with progressive functional decline,” the researchers reported.
Given the lack of meaningful and lasting improvement, her healthcare team decided to try efgartigimod.
The medication works by blocking a protein called the neonatal Fc receptor (FcRn), which normally protects circulating antibodies from being broken down. By inhibiting this protein, efgartigimod accelerates the removal of antibodies involved in autoimmune attacks, potentially reducing disease activity and improving symptoms.
The woman continued taking Firdapse and pyridostigmine while beginning subcutaneous efgartigimod injections at a dose of 1,000 mg once weekly for four weeks.
Efgartigimod improves mobility and daily functioning
Following the first treatment cycle, the woman experienced noticeable improvements in muscle strength and mobility. She was able to walk longer distances and perform daily activities more easily.
However, approximately two months later, before beginning another treatment cycle, she was hospitalized after experiencing a severe worsening of symptoms accompanied by breathing difficulties. Her condition required noninvasive respiratory support.
Efgartigimod was restarted during hospitalization, leading to rapid clinical improvement. She was subsequently able to discontinue respiratory support.
Based on her response, the medical team adjusted the treatment schedule. Initially, injections were administered at two-week intervals before being shortened to a fixed weekly schedule to maintain clinical benefits.
Assessments using standardized clinical scales also showed improvements in the woman’s ability to carry out everyday activities and a reduction in measures of muscle weakness.
At her most recent assessment, she had regained greater independence in daily life, including the ability to perform more complex self-care activities without assistance. Most notably, she could walk 200 meters without help.
Findings support further investigation of efgartigimod for LEMS
The researchers believe the woman’s response provides encouraging evidence for using efgartigimod in people with difficult-to-treat LEMS, including those whose disease is not associated with cancer.
Although a previous report from China described clinical improvements in an older man with cancer-associated LEMS treated with intravenous efgartigimod, the Spanish case provides further evidence supporting the potential use of the medication in this patient population.
Both LEMS and MG are autoimmune disorders that disrupt communication between nerve and muscle cells, resulting in muscle weakness and other symptoms. However, treatment options for LEMS remain limited. Firdapse (amifampridine) is currently the only specifically approved medication for the disease, while some MG treatments, including pyridostigmine, are occasionally prescribed off-label.
The researchers concluded that targeting FcRn could represent a promising treatment strategy for people with treatment-resistant LEMS, regardless of whether their disease is associated with cancer.
Importantly, they highlighted that meaningful clinical improvements were possible even after several years of progressive disability, suggesting that long-standing disease should not automatically rule out targeted treatment approaches.
Contact
Ana Baltasar-Corral
